JYJoyce Yu

Joyce Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joyce Yu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Study of Time to Recovery Following Loss of Neuromonitoring Signal of the Recurrent Laryngeal Nerve in Thyroid Surgery

    by Joyce Yu, Rathina Ragavan, Carolina Nylen, Ahmad Aniss, Stan Sidhu, Alexander Papachristos, Daniel Novakovic, Thomas Stewart, Karl Ng, Hakan Ozoran, et al.

    Background: Injuries of the recurrent laryngeal nerve (RLN) during thyroidectomy although infrequent can lead to major morbidity. Permanent RLN injury is uncommon; however, temporary neurapraxia and loss of signal (LOS) during intraoperative neuromonitoring (IONM) are seen more frequently. This study aimed to identify factors associated with type I (segmental) and II (global) LOS of the RLN during thyroid surgery and to analyze time to recovery of vocal cord function. Methods: This observational retrospective cohort study included 3806 patients (2924 female, 76.8% and 882 male, 23.2%) who underwent hemi or total thyroidectomy in a tertiary center between January 2015 and March 2021. Regression analyses determined factors associated with LOS. Postoperative fibreoptic laryngoscopy was used to measure time to recovery of vocal cord function. Results: RLN LOS occurred in 167 (2.7%) of 5983 nerves at risk during surgery. The rate of Type I and Type II LOS per nerve at risk was 1.4% and 1.3%, respectively. Compared with an indication of malignancy, toxic nodule was associated with 96% increased odds of LOS independent of age and sex ( P < 0.001). Time to recovery was reduced for those with a Type II LOS (median 4 weeks) compared to Type I LOS (median 8 weeks and p = 0.04). Female sex and increasing age were independently associated with a longer duration to return of vocal cord function. Conclusions: Time to recovery of RLN function is significantly reduced for patients with Type II LOS. Toxic thyroid nodules were associated with a higher risk of LOS, and female sex and age are significantly associated with a longer time to recovery.


  • Littré hernia: strangulated Meckel’s diverticulum requiring small intestine resection

    by Joyce Yu, Julian Ip

    Littré hernia is the rare protrusion of a Meckel’s diverticulum (MD) through a hernia sac. We present a rare case of strangulated MD in a woman patient in her 90s, which required a small intestine resection. She presented with 1 day of groin swelling, no features of bowel obstruction and an irreducible hernia on examination. On CT, there were radiological features of strangulation, and the patient was taken for an emergency operation. Findings included a femoral hernia containing strangulated MD with clinical features of ischaemic small bowel. The affected segment was resected, and a side-to-side anastomosis was performed. She recovered well postoperatively. This report emphasises that the clinical diagnosis of Littré hernia can be insidious, and the importance of imaging to aid decision-making.


  • Encountering Arc of Bühler during pancreaticoduodenectomy surgery

    by Joyce Yu, Ali Mohtashami, Jaswinder Samra

    The Arc of Bühler (AoB) is a rare anatomical variant in gastrointestinal vasculature where there is an aberrant anastomotic vessel between coeliac and superior mesenteric arteries. We present a rare case where AoB was noted intraoperatively to have haemodynamically significant flow in the context of coeliac artery stenosis, supplementing arterial supply to the hepatic artery proper via the gastroduodenal artery (GDA). An interpositional jump graft between the aorta and the GDA stump was created using the long saphenous vein, and flow was restored. The patient recovered well postoperatively. This case highlights the importance of understanding variations in gastrointestinal vasculature and the role of preoperative planning.

  • Hyper-Parameter Optimization for Privacy-Preserving Record Linkage

    by Joyce Yu, Jakub Nabaglo, Dinusha Vatsalan, Wilko Henecka, Brian Thorne


  • Open Access

    Efficacy of three key antiviral drugs used to treat orthopoxvirus infections: a systematic review

    by Joyce Yu, Suresh Mahendra Raj

    Background: In a global political climate increasingly concerned about terrorism, bioterrorism agents such as smallpox would undoubtedly be catastrophic. Since WHO announced the eradication of smallpox in 1980, consequently discontinuing the worldwide vaccination campaign, today's population is either immunologically naïve or has waning levels of protection. Further, up to 25% of today's population are contraindicated for smallpox vaccination due to various immunodeficiency conditions. The aim of this study was to evaluate the efficacy of the anti-DNA antivirals cidofovir (CDV), brincidofovir (BCV) and tecovirimat against smallpox and other orthopoxviruses. As of July 2018, FDA approved tecovirimat as the first treatment for smallpox. Methods: A systematic review was conducted to identify relevant literature describing the efficacy and safety of CDV, BCV and tecovirimat including in vitro and in vivo animal studies, human safety trials and human case reports of orthopoxvirus infection. Results: 158 studies met the inclusion criteria. In vitro and in vivo animal studies have found that CDV, BCV and tecovirimat are highly efficacious when used therapeutically and prophylactically. They are partially protective in moderate, but not severe, immunodeficiency models. Clinical trials consistently report BCV and tecovirimat to be safe and well tolerated in humans. In human case reports, CDV, BCV and tecovirimat contributed to recovery from orthopoxvirus infection. BCV and tecovirimat demonstrate strong synergistic effect and may reduce risk of antiviralresistant strains. Conclusion: BCV and tecovirimat are particularly promising as anti-smallpox agents. Gaps in the literature indicate that further research should focus on developing more robust immunodeficiency and antiviral-resistance models.